EVOK Evoke Pharma EV/EBITDA Multiple

Evoke Pharma, Inc. (EVOK) is pursuing an aggressive expansion of B2B sales within the gastrointestinal therapy segment, while current R&D activity is limited to supporting its core product. This chart illustrates the share price dynamics, which currently stand at 0.00. The business relies on the implementation of the innovative Gimoti spray, offering patients with malabsorption an effective nasal alternative to traditional tablets for treating gastroparesis.

EVOK (Evoke Pharma Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 12/27/2025

evokepharma.com (EVOK) - metric breakdowns and financial figures

- current price and projected stock value:

Stock Price Evoke Pharma, Inc|EVOK - Analyst Target Range

- market capitalization data:

Market Capitalization Evoke Pharma Inc|EVOK - Company Buyout Price

- issuer book value statistics:

Accounting Value per Share Evoke Pharma|EVOK - Total Net Assets|Market Capitalization to Book Value Ratio evokepharma.com|EVOK - Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

EVOK - Final Profit|Expected Profit Evoke Pharma, Inc.|EVOK - Market Cap to Net Income|Forward P/E Multiple Evoke Pharma, Inc.|EVOK - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Evoke Pharma Inc|EVOK - Operating profit EBITDA|Earnings per share for the last twelve months Evoke Pharma|EVOK - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months evokepharma.com|EVOK - Net earnings per share growth this year|Earnings growth forecast for next year Evoke Pharma, Inc.

- issuer revenue and sales details:

EVOK - Revenue and Sales Volume|Company Future Sales Volume Evoke Pharma, Inc|EVOK - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Evoke Pharma Inc

Initial company analysis:EVOK (Evoke Pharma, Inc)

Evoke Pharma, Inc. (EVOK) specializes in the commercialization of nasal medications for the treatment of gastroparesis associated with diabetes mellitus. This metric compares the total enterprise value, including net debt, with its operating profit before taxes, depreciation, and amortization. By analyzing the current EV/EBITDA ratio of Evoke Pharma, Inc. (EVOK), an investor determines the market overvaluation of assets relative to actual cash flow, identifying either an undervaluation or a systemic decline of the business.

Competitors of Evoke Pharma, Inc.

EV/EBITDA Multiple PHAT (Phathom Corp)|Enterprise Value to EBITDA Multiple Terns Corp|Ironwood Pharmaceuticals Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Curanex Pharmaceuticals Inc CURX|IMRN (immuron.com.au) - Enterprise Value to EBITDA Ratio|ENTO: Enterprise Value to Operating Income Before Depreciation Ratio|RDHL (RedHill Biopharma Ltd) - EV/EBITDA Multiple|Company Value to EBITDA palisadebio.com PALI|Enterprise Value to EBITDA Ratio JAGX (Jaguar Health, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BIOR (bioratherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic MORF